Why the FDA’s LDT Reversal Is Rewiring Biomarker and Endpoint Strategy in Longevity Trials
Summary The U.S. federal court decision and subsequent FDA action that vacated the 2024 LDT final rule has immediate, practical consequences for how longevity a...
May 4, 2026
0 141